Contact
searchSearch
HMP Global
Quiz

HCC Fundamentals

04/26/2022

Quiz Maker - powered by Riddle

Related Content

TARE vs TACE
TARE Improves Outcomes vs TACE for Large Unresectable HCC
09/14/2026
Laura Simson, MA
A 2026 retrospective study of patients with solitary unresectable hepatocellular carcinoma found that transarterial radioembolization was associated with longer adjusted overall survival and local progression-free survival than transarterial...
A 2026 retrospective study of patients with solitary unresectable hepatocellular carcinoma found that transarterial radioembolization was associated with longer adjusted overall survival and local progression-free survival than transarterial...
A 2026 retrospective study of...
09/14/2026
Vascular Disease Management
Case Report
Off-Label Flow Diverter Stent as a Salvage Technique for Early Post-Liver Transplant Hepatic Arterial Occlusion: A Novel Technique
07/15/2026
Santhosh Babu K.B, MBBS, MD, FNVIR; Ashish Goel, DM, MD; Shyamkumar Nidugala Keshava, MBBS, DMRD, DNB, FRCR, FRANZCR
The authors describe a case report where an off-label technique was performed using a flow diverter stent.
The authors describe a case report where an off-label technique was performed using a flow diverter stent.
The authors describe a case...
07/15/2026
Vascular Disease Management
Ghassan Abou-Alfa headshot
ASCO 2026
Immunotherapy Plus TACE Emerges as a New Option for Intermediate-Stage Hepatocellular Carcinoma
07/13/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses...
07/13/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

AngioDynamics
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
10/08/2026
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
LATHAM, N.Y.--(BUSINESS...
10/08/2026
Vascular Disease Management
Bioresorbable Scaffolds
REVA Medical Announces Motiv Sirolimus-Eluting Bioresorbable Vascular Scaffold Live Case and Late-Breaking BTK Trial Results at VIVA26
10/08/2026
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical,...
10/08/2026
Cath Lab Digest
Lower-Extremity & Stroke Intervention
VIVA26: New Results From AGILITY, PERFORMANCE II, and XTRACT
10/07/2026
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26...
10/07/2026
Cath Lab Digest
Chronic Venous Disease
Medtronic Announces New Prospective, Global Clinical Evidence From the Spectrum Program for VenaSeal™ Closure System in Advanced Chronic Venous Disease
10/07/2026
10/07/2026
Vascular Disease Management
Peripheral Intervention
VIVA26: New Results From POWER PAD II, DISRUPT PAD BTK II, PROMISE III, ELEGANCE, and a TCOT Trial
10/07/2026
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Late-breaking VIVA26 studies...
10/07/2026
Cath Lab Digest
Pulmonary Embolism
VIVA26: New Results From HI-PEITHO, STORM-PE, and TRUST
10/07/2026
Three late-breaking VIVA26 studies reported new data on bleeding risk with ultrasound-facilitated catheter-directed thrombolysis, wearable-based functional recovery after intermediate-high-risk PE, and Laguna Thrombectomy System™ safety and...
Three late-breaking VIVA26 studies reported new data on bleeding risk with ultrasound-facilitated catheter-directed thrombolysis, wearable-based functional recovery after intermediate-high-risk PE, and Laguna Thrombectomy System™ safety and...
Three late-breaking VIVA26...
10/07/2026
Cath Lab Digest
Peripheral Intervention
VIVA26: New Results From SELUTION4SFA, SirPAD, SUCCESS PTA, CADET-PAD, Esprit BTK, and MOTIV BTK
10/07/2026
Six late-breaking VIVA26 studies reported new data on sirolimus-based balloon and resorbable scaffold therapies, as well as adjunctive pharmacologic treatment, for patients with PAD and chronic limb-threatening ischemia.
Six late-breaking VIVA26 studies reported new data on sirolimus-based balloon and resorbable scaffold therapies, as well as adjunctive pharmacologic treatment, for patients with PAD and chronic limb-threatening ischemia.
Six late-breaking VIVA26 studies...
10/07/2026
Cath Lab Digest
iliac artery disease
VIVA 2026: BD's Revello Covered Stent Shows 97.2% Primary Patency in AGILITY Trial
10/07/2026
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Data through 9 months of...
10/07/2026
Cath Lab Digest
Pulmonary Embolism
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
10/07/2026
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery.
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery.
Wearable-derived data provide...
10/07/2026
Cath Lab Digest
atherectomy
Nipro Corporation Announces Completion of Patient Enrollment in the GREAT U.S. Pivotal Trial Evaluating the Golazo Peripheral Atherectomy System
10/07/2026
Completion of enrollment in the GREAT trial marks an important milestone toward FDA 510(k) submission.
Completion of enrollment in the GREAT trial marks an important milestone toward FDA 510(k) submission.
Completion of enrollment in the...
10/07/2026
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use